neo-pentyl pyrrolidine-1-carboxylate | 1609376-18-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: neo-pentyl pyrrolidine-1-carboxylate
• 英文别名: 2,2-Dimethylpropyl pyrrolidine-1-carboxylate
• CAS: 1609376-18-2
• 化学式: C₁₀H₁₉NO₂
• 分子量: 185.266
• InChiKey: JUCZWFSMAWJITO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  neo-pentyl 1H-imidazole-1-carboxylate 在 三乙胺 作用下， 以 乙腈 为溶剂， 反应 48.0h， 生成 neo-pentyl pyrrolidine-1-carboxylate
  参考文献：
  名称：

  Method for the synthesis of N-alkyl-O-alkyl carbamates

  摘要：

  合成N-烷基，O-烷基氨基甲酸酯的简单三步方法。

  DOI：

  10.1039/c4ra00373j

文献信息

• CYCLOALKYL-CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20200062727A1

  公开（公告）日：2020-02-27

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof, which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

  本发明揭示了化合物的结构式（I），及其在药学上可接受的盐，这些化合物抑制凋亡信号调节激酶1（ASK-1），与自身免疫性疾病、神经退行性疾病、炎症性疾病、慢性肾脏疾病、心血管疾病有关。本发明还涉及包含上述化合物的药物组合物，用于治疗患有ASK-1相关疾病的受试者。该发明还涉及通过给予含有本发明化合物的药物组合物来治疗受试者的ASK-1相关疾病的方法。本发明特别涉及治疗与肝脂肪变性相关的ASK-1的方法，包括非酒精性脂肪肝病（NAFLD）和非酒精性脂肪性肝炎疾病（NASH）。
• Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same
  申请人：CHO Dong-Gyu

  公开号：US20100004440A1

  公开（公告）日：2010-01-07

  The present invention relates to an acyclic nucleoside phosphonate derivative which is useful as an antiviral agent (particularly, against hepatitis B virus), pharmaceutically acceptable salts, stereoisomers, and a process for the preparation thereof.

  本发明涉及一种无环核苷酸膦酸酯衍生物，其可用作抗病毒剂（特别是针对乙型肝炎病毒），药学上可接受的盐，立体异构体以及其制备方法。
• PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP3235814A1

  公开（公告）日：2017-10-25

  Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.

  公开了式 1 的化合物、 或其药学上可接受的盐，其中 R1、R2、R3 和 R4 在说明书中定义。本公开还涉及制备式 1 化合物的材料和方法、含有这些化合物的药物组合物，以及它们在治疗 I 型超敏反应、自身免疫性疾病、炎症性疾病、癌症、非恶性增生性疾病和其他与 BTK 有关的疾病方面的用途。
• Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US10968199B2

  公开（公告）日：2021-04-06

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof, which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

  本发明公开了式 (I) 的化合物、 及其药学上可接受的盐类，它们能抑制与自身免疫性疾病、神经退行性疾病、炎症性疾病、慢性肾病、心血管疾病相关的凋亡信号调节激酶 1 (ASK-1)。本发明进一步涉及包含上述化合物的药物组合物，用于给患有 ASK-1 相关疾病的患者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者 ASK-1 相关疾病的方法。本发明特别涉及治疗与肝脂肪变性相关的ASK-1的方法，包括非酒精性脂肪肝（NAFLD）和非酒精性脂肪性肝炎（NASH）。
• NOVEL AMINO PYRIMIDINE DERIVATIVES
  申请人：Novartis AG

  公开号：EP3299368B1

  公开（公告）日：2020-02-26